Study: Gene Therapy For Treatment of Deafness Within Reach!

Good news for people who wish to hear! Scientists are now way closer to gene therapy for deafness revealing the revolutionary technique that could fix faulty DNA to improve response in people with genetic hearing loss. The study has showed positive results in mice.

Scientists from the Ecole Polytechnique Federale de Lausanne and the Boston Children’s Hospital, tested hearing in newborn mutant mice by seeing how high they jumped when startled by a noise.

The team focused on a gene called TMC1, which is a common cause of human genetic deafness, accounting for 4 to 8 % of cases. But other forms of hereditary deafness could also be fixed using the same strategy. To be noted, however, is that there are varying range of deafness and each needs a different approach to treat it.

Interestingly, hearing loss in older people is noise-induced or age-related, but at least 50% deafness that occurs before a baby learns to speak is caused by defects in one of more than 70 individual genes.

It is these infants Swiss and U.S. researchers hope to help, after showing that replacing a mutated gene improved the function of hair cells of the inner ear and partially restored hearing in deaf mice.

Another clinical trial – conducted through Novartis is under way to help a different category of deaf people – people who tragically lost their hearing through damage or disease.

After missteps in the late 1990s and early 2000s, gene therapy is witnessing a great revival, with positive clinical results recently in conditions ranging from blood diseases to blindness.

“We are somewhat late in the auditory field but I think we are getting there now,” said Tobias Moser of the University Medical Center Gottingen, Germany, who was not involved in the new research. “It’s an exciting time for gene therapy in hearing.”

A crucial current optimism is the development of better and safer viral delivery systems for getting corrective genes into the body. In the case of deafness, this involves injecting a gene-carrying engineered virus into the inner ear.

There are currently no approved disease-modifying treatments for disabling hearing loss, which affects some 360 million people, or 5 percent of the world’s population, according to the World Health Organization.

Hearing aids can amplify sounds, while cochlear implants turn sounds into electrical signals for the brain to decode, but such devices are not able to replace natural healing.

Jeffrey Holt of Boston Children’s said the technique still needed “tweaking” but he hopes clinical trials will start within five to 10 years.

Work at Novartis is more advanced, with the first patient treated last October in an early-stage clinical trial that will recruit 45 subjects in the United States, with results due in 2017. (here)

The Swiss company’s product, acquired in a 2010 deal with GenVec worth up to $214 million, delivers a gene called Atoh1 that acts as a master switch for turning on the growth of inner ear hair cells that are central to hearing.

Novartis research head Mark Fishman describes it as a “spare parts” approach to fixing ageing-related frailty.

The process offers hope to adults whose hair cells have been damaged by excessive noise, disease or exposure to certain drugs, including some antibiotics. But it will not help the one to three babies per 1,000 born with severe genetic hearing loss in both ears.


Leave a Reply

Your email address will not be published. Required fields are marked *